At Emerald Bioscience, we are focused on advancing the medical benefits of cannabinoid-based therapies through our novel, proprietary, multi-cannabinoid drug platform for the treatment of significant unmet medical needs. This bioengineered platform, pioneered by the University of Mississippi, is considered an early mover in cannabinoid drug development. Modifying the molecules of the cannabis plant and creating synthetic cannabinoid derivatives, results in an optimized cannabinoid technology that enhances bioavailability and delivers more predictable pharmacokinetics.
Meet Our Team
Glaucoma. MRSA. Dry Eye Syndrome.
See the world's future through the potential of our proprietary cannabinoid-based therapies.
Our proprietary therapies continue to advance through preclinical and clinical development for various global medical indications.
Our platform is designed to enhance bioavailability and deliver more predictable pharmacokinetics.
Emerald Bioscience continues to establish relationships with industry leaders to further advance our research.
What are Cannabinoids?
October 15, 2019 | Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model
October 15, 2019 | Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma
October 3, 2019 | Glauconix Biosciences and University of Mississippi to Present Research Data Related to Emerald Bioscience’s Glaucoma Drug Candidate, NB1111, at 2019 American Academy of Ophthalmology Annual Meeting
August 26, 2019 | Emerald Bioscience Appoints Chief Medical Officer and Executive Director, Clinical Operations
Sign up for our Newsletter
Receive breaking news first!